Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MediciNova, EA Pharma, Aptinyx, Toray, Enveric

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | MediciNova, EA Pharma, Aptinyx, Toray, Enveric
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy Induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chemotherapy Induced Peripheral Neuropathy Market. 

The Chemotherapy Induced Peripheral Neuropathy Pipeline report embraces in-depth commercial, regulatory, and Chemotherapy Induced Peripheral Neuropathy clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Chemotherapy Induced Peripheral Neuropathy drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Chemotherapy Induced Peripheral Neuropathy treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Chemotherapy Induced Peripheral Neuropathy therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Chemotherapy Induced Peripheral Neuropathy companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Chemotherapy Induced Peripheral Neuropathy drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chemotherapy Induced Peripheral Neuropathy therapeutic market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Chemotherapy-Induced Peripheral Neuropathy Pipeline Analysis

Analysis of Emerging Chemotherapy-Induced Peripheral Neuropathy Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravitreal

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Chemotherapy Induced Peripheral Neuropathy Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN). Currently, MediciNova is leading the therapeutics market with its Chemotherapy Induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage of clinical development.

Chemotherapy Induced Peripheral Neuropathy (CIPN) Companies Actively Working in the Therapeutic Market Include:

  • MediciNova

  • Asahi Kasei Pharma Corp.

  • AnnJi Pharmaceutical

  • EA Pharma

  • Aptinyx

  • Sonnet Biotherapeutics Holdings

  • Toray

  • Solasia Pharma

  • Enveric Biosciences

  • Regenacy Pharmaceuticals

  • NeuroBo Pharmaceuticals

And Many Others

Emerging and Marketed Chemotherapy Induced Peripheral Neuropathy (CIPN) Drugs Covered in the Report Include:

  • MN-166 (ibudilast): MediciNova

  • ART-123: Asahi Kasei Pharma Corp.

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Chemotherapy Induced Peripheral Neuropathy Companies Working in the Market:

https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Chemotherapy Induced Peripheral Neuropathy Treatment Patterns

4. Chemotherapy Induced Peripheral Neuropathy – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chemotherapy Induced Peripheral Neuropathy Late Stage Products (Phase-III)

7. Chemotherapy Induced Peripheral Neuropathy Mid-Stage Products (Phase-II)

8. Chemotherapy Induced Peripheral Neuropathy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chemotherapy Induced Peripheral Neuropathy Discontinued Products

13. Chemotherapy Induced Peripheral Neuropathy Product Profiles

14. Major Chemotherapy Induced Peripheral Neuropathy Companies in the Market

15. Key Products in the Chemotherapy Induced Peripheral Neuropathy Therapeutics Segment

16. Dormant and Discontinued Products

17. Chemotherapy Induced Peripheral Neuropathy Unmet Needs

18. Chemotherapy Induced Peripheral Neuropathy Future Perspectives

19. Chemotherapy Induced Peripheral Neuropathy Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports by DelveInsight

CART-related Neurotoxicity (NT) Market

“CART-related Neurotoxicity (NT) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the CART-related Neurotoxicity market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the CART-related Neurotoxicity market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: